Some individuals featured may be participating in Biogen clinical trials.
SPINRAZA is a modified antisense oligonucleotide designed to target an underlying cause of motor neuron loss
SPINRAZA has been studied in the longest SMA clinical trial program to date3
If patients or caregivers are experiencing nonmedical barriers to accessing treatment–such as the cost of SPINRAZA–Biogen may be able to help
“Around age 32, I had moved across the country and started working with a new doctor. I was feeling weaker but learning to accept it. My doctor mentioned a treatment to me